SCHEMBL101867

SCHEMBL101867

N/C(=N\O)c1ccc(Cl)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.65
LMNA P02545 1/20 0.65
ALOX15 P16050 1/20 0.65
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
RAB9A P51151 7/20 0.50
NPC1 O15118 6/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
HPGD P15428 4/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
TSHR P16473 2/20 0.50
CASP1 P29466 1/20 0.50
CASP3 P42574 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
MAPT P10636 5/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
GABRA1 P14867 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL101868 1.00 USP2 (0.65) USP2LMNAALOX15MEN1KMT2A
SCHEMBL29478736 1.00 USP2 (0.65) USP2LMNAALOX15MEN1KMT2A
SCHEMBL102768 0.83 ALDH1A1 (0.50) USP2LMNAALOX15MEN1KMT2A
SCHEMBL102769 0.83 ALDH1A1 (0.50) USP2LMNAALOX15MEN1KMT2A
SCHEMBL1949078 0.82 CA1 (0.47) USP2LMNAALOX15MEN1KMT2A
SCHEMBL1949077 0.82 CA1 (0.47) USP2LMNAALOX15MEN1KMT2A
SCHEMBL4947860 0.82 ALOX15 (0.49) USP2LMNAALOX15MEN1KMT2A
SCHEMBL12186540 0.82 HSD17B10 (0.46) USP2LMNAALOX15MEN1KMT2A
SCHEMBL17738048 0.80 NPC1 (0.53) USP2LMNAALOX15MEN1KMT2A
SCHEMBL17730401 0.80 NPC1 (0.53) USP2LMNAALOX15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 US disclosed
CN-114269340-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-04-01 CN disclosed
EP-3962481-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2022-03-09 EP disclosed
WO-2020227101-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2020-11-12 WO disclosed
EP-2956453-B1 3,5-DISUBSTITUTED-4,5-DIHYDRO-1,2,4-OXADIAZOLES FOR CONTROLLING NEMATODE PESTS MONSANTO TECHNOLOGY LLC (US) 2019-10-02 EP disclosed
US-9232800-B2 3,5-disubstituted-4,5-dihydro-1,2,4-oxadiazoles and compositions and methods for controlling nematode pests MONSANTO TECHNOLOGY LLC (US) 2016-01-12 US disclosed
EP-2956453-A1 3,5-DISUBSTITUTED-4,5-DIHYDRO-1,2,4-OXADIAZOLES FOR CONTROLLING NEMATODE PESTS Monsanto Technology LLC (US) 2015-12-23 EP disclosed
US-8883826-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-11-11 US disclosed
WO-2014127195-A1 3,5-DISUBSTITUTED-4,5-DIHYDRO-1,2,4-OXADIAZOLES FOR CONTROLLING NEMATODE PESTS MONSANTO TECHNOLOGY LLC (US) 2014-08-21 WO disclosed
US-20140235439-A1 3,5-DISUBSTITUTED-4,5-DIHYDRO-1,2,4-OXADIAZOLES AND COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODE PESTS MONSANTO TECHNOLOGY LLC (US) 2014-08-21 US disclosed
US-8674106-B2 Alkynyl derivatives as modulators of metabotropic glutamate receptors ADDEX PHARMA SA (CH) 2014-03-18 US disclosed
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-07-11 US disclosed
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2012-11-01 US disclosed
EP-2426115-A2 Alkynyl derivatives as modulators of metabotropic glutamate receptors Addex Pharma SA (CH) 2012-03-07 EP disclosed
US-8101637-B2 Alkynyl derivatives as modulators of metatropic glutamate receptors ADDEX PHARMA SA (CH) 2012-01-24 US disclosed
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2009-05-14 US disclosed
EP-1765795-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharmaceuticals SA (CH) 2007-03-28 EP disclosed
WO-2005123703-A2 ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178631-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 USP2 2594/4885LMNA 4407/4885ALOX15 1300/4885
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS GRM5, GRM2, GRM1 USP2 2626/4885LMNA 4715/4885ALOX15 1607/4885
US-20140235439-A1 3,5-DISUBSTITUTED-4,5-DIHYDRO-1,2,4-OXADIAZOLES AND COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODE PESTS ATL3, DDT, DNPH1 USP2 610/4885LMNA 3507/4885ALOX15 723/4885
US-20120277237-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM5, GRM1, GRM2 USP2 2594/4885LMNA 4407/4885ALOX15 1300/4885
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 USP2 3757/4885LMNA 1423/4885ALOX15 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.